Updated for 2026
WHNP contraception: CDC MEC, LARC management, and counselling across the reproductive lifespan
Contraceptive counselling and management are core WHNP competencies. The CDC Medical Eligibility Criteria (MEC) is the evidence-based framework for contraceptive safety in women with complex medical conditions. WHNP certification tests MEC categories, LARC (long-acting reversible contraception) counselling and management, reproductive justice principles, and contraceptive failure and management.
Educational purpose: This content is for exam preparation and professional development only. It is not intended for clinical decision-making. Always follow current guidelines, institutional policies, and scope of practice.
CDC Medical Eligibility Criteria — applying to complex clinical scenarios
CDC MEC provides evidence-based guidance on contraceptive safety in women with medical conditions. MEC categories: 1 (no restriction), 2 (advantages outweigh risks — generally use), 3 (risks generally outweigh advantages — use with caution and monitoring), 4 (unacceptable health risk — do not use).
Key MEC Category 4 contraindications (memorise for exam):
- Combined hormonal contraceptives (pills/patch/ring): Breastfeeding <6 weeks, DVT/PE (current), migraine with aura, ≥35 years + smoking ≥15 cigarettes/day, history of ischaemic heart disease, multiple CVD risk factors, known thrombogenic mutations, hypertension ≥160/100
- Levonorgestrel IUD: Current or recent breast cancer (Category 4)
- Copper IUD: Current PID or STI risk, unexplained vaginal bleeding, pregnancy, current cervical cancer
- Progestin implant/DMPA: Current or recent breast cancer
Postpartum contraception: Immediate postpartum LARC (IUD or implant within 10 minutes of placenta delivery) is safe and highly effective. Progestin-only methods safe in breastfeeding mothers from delivery. Combined hormonal: avoid <6 weeks postpartum (Category 4 — VTE risk; breastfeeding concerns); <6 months postpartum in breastfeeding women is Category 2–3 depending on status.
Long-acting reversible contraception — IUD types and implant
Levonorgestrel IUDs (hormonal):
- Mirena (52 mg LNG): 8 years (FDA label), reduces or eliminates menstrual bleeding — FDA-approved for menorrhagia; improves dysmenorrhoea; protects against endometrial hyperplasia in women on systemic oestrogen
- Kyleena (19.5 mg LNG): 5 years; smaller frame — preferred for nulliparous women; lighter menstrual effect
- Liletta (52 mg LNG): 8 years; comparable to Mirena
- Skyla (13.5 mg LNG): 3 years; smallest frame — designed for adolescents and nulliparous women
Copper IUD (Paragard): 10+ years (labelled for 10; evidence supports 12+ years). Non-hormonal — ideal for patients wanting non-hormonal contraception or those with contraindications to hormonal methods. Most effective emergency contraception (within 5 days of unprotected intercourse). Increases menstrual bleeding and cramping.
Etonogestrel implant (Nexplanon): Single progestin rod placed in inner upper arm; provides 3 years contraception. >99% effective. Irregular bleeding is the most common side effect. Remove: at 3 years (or when patient wishes); irregular bleeding not responsive to treatment; weight gain concerns addressed by counselling (evidence mixed for weight gain).
Frequently asked questions
- A 19-year-old with sickle cell disease wants contraception. What does CDC MEC recommend?
- Sickle cell disease (SCD) and contraceptive safety: CHC (combined hormonal) = CDC MEC Category 2 for SCD — benefits generally outweigh risks; oestrogen has both potential thrombotic effects (negative in SCD) and anti-sickling effects from reduced red cell breakdown. DMPA (depot medroxyprogesterone acetate) = Category 1 for SCD — actually beneficial, as it may reduce sickle crises through amenorrhoea and possibly anti-sickling effects. LNG IUD = Category 1 or 2 for SCD. Progestin implant = Category 1. Copper IUD = Category 2 for SCD (generally acceptable). Practical recommendation: LARC is preferred for SCD (progestin-only IUD or implant = most appropriate first-line recommendation balancing high efficacy + minimal systemic effects + potential benefit of reduced bleeding). DMPA is also highly appropriate and may improve SCD symptoms through amenorrhoea. Avoid CHC if other VTE risk factors coexist.
Clinically reviewed by NurseNest Clinical Review Team · Last updated 2026-06-10 · For educational purposes only · Review policy